exact sciences corp. - EXAS
EXAS
Close Chg Chg %
52.70 1.22 2.31%
Open Market
53.92
+1.22 (2.31%)
Volume: 881.53K
Last Updated:
Nov 21, 2024, 12:48 PM EDT
Company Overview: exact sciences corp. - EXAS
EXAS Key Data
| Open $52.49 | Day Range 52.17 - 54.02 |
| 52 Week Range 40.62 - 79.47 | Market Cap $9.75B |
| Shares Outstanding 185.08M | Public Float 182.38M |
| Beta 1.27 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.17 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 3.18M |
EXAS Performance
| 1 Week | 6.83% | ||
| 1 Month | -23.74% | ||
| 3 Months | -11.73% | ||
| 1 Year | -20.14% | ||
| 5 Years | -32.14% |
EXAS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
23
Full Ratings ➔
About exact sciences corp. - EXAS
EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.
EXAS At a Glance
EXACT Sciences Corp.
5505 Endeavor Lane
Madison, Wisconsin 53719
| Phone | 1-608-284-5700 | Revenue | 2.50B | |
| Industry | Medical Specialties | Net Income | -204,149,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 19.934% | |
| Fiscal Year-end | 12 / 2024 | Employees | 6,600 | |
| View SEC Filings |
EXAS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.331 |
| Price to Book Ratio | 4.266 |
| Price to Cash Flow Ratio | 85.365 |
| Enterprise Value to EBITDA | -197.949 |
| Enterprise Value to Sales | 6.047 |
| Total Debt to Enterprise Value | 0.17 |
EXAS Efficiency
| Revenue/Employee | 378,752.424 |
| Income Per Employee | -30,931.667 |
| Receivables Turnover | 12.052 |
| Total Asset Turnover | 0.367 |
EXAS Liquidity
| Current Ratio | 2.321 |
| Quick Ratio | 2.073 |
| Cash Ratio | 1.511 |
EXAS Profitability
| Gross Margin | 70.141 |
| Operating Margin | -12.436 |
| Pretax Margin | -8.071 |
| Net Margin | -8.167 |
| Return on Assets | -2.998 |
| Return on Equity | -6.598 |
| Return on Total Capital | -3.574 |
| Return on Invested Capital | -3.679 |
EXAS Capital Structure
| Total Debt to Total Equity | 81.602 |
| Total Debt to Total Capital | 44.934 |
| Total Debt to Total Assets | 37.083 |
| Long-Term Debt to Equity | 78.938 |
| Long-Term Debt to Total Capital | 43.468 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Exact Sciences Corp. - EXAS
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 1.49B | 1.77B | 2.08B | 2.50B | |
Sales Growth
| +70.19% | +18.49% | +17.95% | +19.93% | |
Cost of Goods Sold (COGS) incl D&A
| 447.72M | 553.76M | 671.84M | 746.41M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 179.08M | 206.17M | 226.20M | 234.50M | |
Depreciation
| 85.68M | 111.17M | 128.75M | 142.34M | |
Amortization of Intangibles
| 93.40M | 95.00M | 97.45M | 92.16M | |
COGS Growth
| +92.36% | +23.68% | +21.32% | +11.10% | |
Gross Income
| 1.04B | 1.21B | 1.41B | 1.75B | |
Gross Income Growth
| +62.18% | +16.26% | +16.41% | +24.14% | |
Gross Profit Margin
| +69.98% | +68.66% | +67.77% | +70.14% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.19B | 1.94B | 2.03B | 2.06B | |
Research & Development
| 141.45M | 300.35M | 393.42M | 425.88M | |
Other SG&A
| 1.05B | 1.64B | 1.64B | 1.64B | |
SGA Growth
| +45.86% | +63.50% | +4.67% | +1.52% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 605.05M | 95.97M | (40.65M) | (7.10M) | |
EBIT after Unusual Expense
| (749.47M) | (825.18M) | (580.27M) | (303.76M) | |
Non Operating Income/Expense
| (19.60M) | 1.28M | (32.67M) | 111.14M | |
Non-Operating Interest Income
| - | - | 5.50M | 1.79M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 88.03M | 18.61M | 19.63M | 9.12M | |
Interest Expense Growth
| +72.47% | -78.86% | +5.53% | -53.53% | |
Gross Interest Expense
| 88.03M | 18.61M | 19.63M | 9.12M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (857.11M) | (842.51M) | (632.57M) | (201.75M) | |
Pretax Income Growth
| -218.80% | +1.70% | +24.92% | +68.11% | |
Pretax Margin
| -57.47% | -47.68% | -30.35% | -8.07% | |
Income Tax
| (8.57M) | (246.88M) | (9.06M) | 2.40M | |
Income Tax - Current - Domestic
| 799.00K | 1.39M | 2.17M | 2.27M | |
Income Tax - Current - Foreign
| 933.00K | 4.90M | 1.13M | 2.56M | |
Income Tax - Deferred - Domestic
| (10.42M) | (253.22M) | (12.22M) | 566.00K | |
Income Tax - Deferred - Foreign
| 120.00K | 54.00K | (147.00K) | (2.99M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (848.53M) | (595.63M) | (623.51M) | (204.15M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (848.53M) | (595.63M) | (623.51M) | (204.15M) | |
Net Income Growth
| -910.24% | +29.81% | -4.68% | +67.26% | |
Net Margin Growth
| -56.90% | -33.71% | -29.91% | -8.17% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (848.53M) | (595.63M) | (623.51M) | (204.15M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (848.53M) | (595.63M) | (623.51M) | (204.15M) | |
EPS (Basic)
| -5.6143 | -3.4761 | -3.5356 | -1.1332 | |
EPS (Basic) Growth
| -777.37% | +38.08% | -1.71% | +67.95% | |
Basic Shares Outstanding
| 151.14M | 171.35M | 176.35M | 180.14M | |
EPS (Diluted)
| -5.6143 | -3.4761 | -3.5356 | -1.1332 | |
EPS (Diluted) Growth
| -777.37% | +38.08% | -1.71% | +67.95% | |
Diluted Shares Outstanding
| 151.14M | 171.35M | 176.35M | 180.14M | |
EBITDA
| 34.66M | (523.04M) | (394.72M) | (76.36M) | |
EBITDA Growth
| +130.06% | -1,608.88% | +24.53% | +80.65% | |
EBITDA Margin
| +2.32% | -29.60% | -18.94% | -3.05% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 71.19 | |
| Number of Ratings | 23 | Current Quarters Estimate | -0.33 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -1.183 | |
| Last Quarter’s Earnings | -0.21 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.13 | Next Fiscal Year Estimate | -0.273 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 19 | 19 | 17 | 23 |
| Mean Estimate | -0.33 | -0.30 | -1.18 | -0.27 |
| High Estimates | -0.15 | 0.22 | -0.72 | 0.97 |
| Low Estimate | -0.49 | -0.56 | -1.39 | -1.19 |
| Coefficient of Variance | -24.09 | -60.62 | -11.91 | -161.58 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 18 | 20 | 20 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 4 | 4 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Exact Sciences Corp. - EXAS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Exact Sciences Corp. - EXAS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 14, 2024 | Kevin T. Conroy President and CEO; Director | 1,074,191 | Open market or private purchase of non-derivative security Non-derivative transaction at $51.35 per share | 55,159,707.85 |
| Jun 18, 2024 | Michael J. Barber Director | 5,444 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 18, 2024 | Kathleen Sebelius Director | 31,888 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 18, 2024 | Shacey Petrovic Director | 15,911 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 18, 2024 | Paul J. Clancy Director | 20,145 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 18, 2024 | Michael J. Barber Director | 7,422 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 18, 2024 | D. Scott Coward Director | 50,088 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 18, 2024 | Katherine Zanotti Director | 70,073 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 18, 2024 | Daniel Joseph Levangie Director | 28,419 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 18, 2024 | James Edward Doyle Director | 55,554 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 3, 2024 | Everett V. Cunningham Chief Commercial Officer | 47,178 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $30.02 per share | 1,416,283.56 |
| May 3, 2024 | Everett V. Cunningham Chief Commercial Officer | 47,042 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $60.15 per share | 2,829,576.30 |
| May 3, 2024 | Kevin T. Conroy President and CEO; Director | 1,156,191 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $60.15 per share | 69,544,888.65 |
| May 3, 2024 | Kevin T. Conroy President and CEO; Director | 1,157,346 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $30.02 per share | 34,743,526.92 |
| May 3, 2024 | Jeffrey Thomas Elliott Chief Financial Officer | 11,224 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 3, 2024 | Jeffrey Thomas Elliott Chief Financial Officer | 11,931 | Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $30.02 per share | 358,168.62 |
| May 3, 2024 | Jeffrey Thomas Elliott Chief Financial Officer | 11,795 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $60.15 per share | 709,469.25 |
| May 3, 2024 | Jake Orville General Manager, Screening | 14,542 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 3, 2024 | Jake Orville General Manager, Screening | 14,440 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $60.15 per share | 868,566.00 |
| May 3, 2024 | D. Scott Coward Director | 44,644 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $60.15 per share | 2,685,336.60 |